Table 3.

The biological activities and molecular effects of 3′-hydroxypterostilbene.

Modes/Treatments	Model used	Mechanism	Reference
Leukemia
3′-hydroxypterostilbene (0.7–5μM)	HL60, K562, HUT78 HL60-R, K562-ADR	↓Cell proliferation, ↑apoptosis, ↓mitochondrial membrane potential	Tolomeo et al, 2005 [20]
Colon cancer
3′-hydroxypterostilbene (5–50μM)	COLO 205, HCT-116, HT-29	↑Apoptosis, ↑caspase-3, -8, -9, ↓mTOR/p70S6K, ↓PI3K/Akt, ↓MAPKs, ↓p-ERK1/2, ↓p-JNK1/2, ↑autophagy, ↑LC3 II	Cheng et al, 2014 [28]
3′-hydroxypterostilbene (10 mg/kg BW)	COLO 205 Xenograft nude mice	↓Tumor volume, ↓tumor weight, ↓COX-2, ↓MMP-9, ↓VEGF, ↓cyclin D1,↑caspase-3	Cheng et al, 2014 [28]
3′-hydroxypterostilbene (12–50 μg/mL)	HCT-116, MDA-MB-231, PC-3, HepG2, 3T3-L1, enzyme incubation	↓Cell viability, ↓adipogenesis,↓Sirt-1	Takemoto et al, 2015 [79]

COX-2 = cyclooxygenase-2; LC3 II = autophagy-related protein light chain 3 II; MAPKs = mitogen-activated protein kinases; MMP-9 = matrix metallopeptidase 9; mTOR = mammalian target of rapamycin; p70S6K = 70 kDa ribosomal protein S6 kinase; p-ERK1/2 = phosphorylated-extracellular signal-regulated kinase 1/2; PI3K = phosphatidylinositol 3-kinase; p-JNK1/2 = phospho-JNK1/2; VEGF = vascular endothelial growth factor.